After canceling meeting of independent advisers, FDA issues 2025-26 flu vaccine recommendations
The FDA's Vaccines and Related Biological Products Advisory Committee had been scheduled to meet Thursday to weigh in on the composition of the flu shots, but that session was canceled without explanation in late February.
Instead, experts from within the FDA, the US Centers for Disease Control and Prevention and the US Department of Defense gathered Thursday to go over surveillance data from the US and around the world about flu viruses that are currently circulating.
The FDA is recommending that flu vaccines for the 2025-26 season be trivalent, protecting against two strains of influenza A and one of influenza B.
'The FDA anticipates that there will be an adequate and diverse supply of approved trivalent seasonal influenza vaccines' for the upcoming virus season, it said in a statement.
There are several ways to make flu vaccines, but the most common is to grow the selected candidate viruses in chicken eggs, a painstaking operation that takes months to finish.
For that reason, selection of the strains that will be included in flu vaccines is carefully orchestrated to be sure manufacturers can deliver the shots to doctors' offices and pharmacies in time.
In order for flu vaccines to be sold in the US, they must contain strains that are officially selected by the FDA.
That decision typically comes after a meeting of the World Health Organization's Global Influenza Surveillance and Response System, a network of seven collaborating centers and four essential regulatory labs, which are based in the US, UK, Japan, China, Russia and Australia. Both the CDC and the FDA are members.
These experts meet twice a year — in the fall and spring — to choose strains for countries in the Southern and Northern Hemispheres. WHO's own vaccine recommendations for 2025-26 generally parallel those of the FDA.
Typically, the 17-member FDA vaccine committee would meet next and publicly discuss the recommendation and make its own endorsement, and then the agency would make its final decision.
The cancellation of the committee meeting had prompted concerns about the timing of and access to flu shots for this fall. 'I'm glad that they've come out with the influenza recommendation in a timely manner,' Dr. Paul Offit, a member of the independent advisory committee and director of the Vaccine Education Center at the Philadelphia Children's Hospital, said Thursday.
The 2024-25 flu season – the worst in the US in more than a decade – is believed to have peaked in early February. The CDC estimated in early March that there had been at least 40 million illnesses, 520,000 hospitalizations and 22,000 deaths caused by flu this season.
CNN's Meg Tirrell contributed to this report.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
9 minutes ago
- CNBC
Sarepta shares plunge 30% as future of its gene therapy appears at risk
Shares of Sarepta Therapeutics plunged more than 30% on Friday as the future of its approved gene therapy treatment appeared at risk. The Food and Drug Administration will request that the company voluntarily stop all shipments of the treatment, Elevidys, a person familiar with the matter told CNBC. Separately, FDA Commissioner Marty Makary told Bloomberg News the agency is considering whether the company's gene therapy should stay on the market. The FDA has been investigating two patient deaths tied to Elevidys. The company also reported a third death tied to a separate experimental gene therapy. Sarepta did not immediately respond to a request for comment.
Bloomberg
40 minutes ago
- Bloomberg
FDA Is Investigating If Sarepta's Gene Therapy Should Stay on Market
US Food and Drug Administration Commissioner Marty Makary said he's 'taking a hard look' at whether a gene therapy from Sarepta Therapeutics Inc. should remain on the market. Makary made the comments in an interview with Bloomberg News.
Associated Press
an hour ago
- Associated Press
New Study Raises Red Flags About Ingredients Found in Gas Station Heroin
Research conducted on dogs shows serious adverse effects at doses far lower than commonly sold amounts The Stop Gas Station Heroin coalition is sounding the alarm after reviewing a new animal study commissioned by CBD American Shaman, a Missouri-based company that sells '7' products in stores across the country. The study, which tested the effects of increasing doses of two lab-made substances — '7' (7-hydroxymitragynine) and 'Pseudo' (mitragynine pseudoindoxyl) — was funded to support the company's bid for FDA drug approval. But the research methods and results raise serious red flags for consumers of Gas Station Heroin. First, a clear conflict of interest occurred in conducting this study: CBD American Shaman has been illegally selling 7 products as dietary supplements since 2022, and the research was released by Holistic Alternative Recovery Trust (HART), a group with a financial stake in 7 and Pseudo products. Second, the study suggests these drugs may be far more dangerous than their labels imply: CBD American Shaman tells consumers that 7.5 milligrams, or half a tablet, is a safe serving. But based on the study's own data, that amount may be more than 25 times higher than what would be considered safe for human consumption. Using standard FDA methods to translate the effects seen in dogs to humans, Stop Gas Station Heroin estimates that just 0.3 milligrams could cross the threshold for risk. Yet many consumers of these products are unknowingly ingesting significantly greater amounts. Moreover, the study points to clear risks of addiction and dependency with misuse. 'These are not natural products. They are chemically altered, unapproved pharmaceutical drugs being marketed as herbal remedies,' said Matthew Lowe, Executive Director of Stop Gas Station Heroin. 'You can't just slap a 'dietary supplement' label on a drug and skip the safety trials.' CBD American Shaman and other purveyors of Gas Station Heroin have marketed 7 and Pseudo products as supplements formulated to cure, treat, and mitigate disease — namely, chronic pain and opioid use disorder — even though the products have never been approved by the FDA for any medical use. If companies like CBD American Shaman want to sell these substances legally, they must demonstrate the drugs' safety and effectiveness through a rigorous series of clinical trials and submit the results to the FDA as part of the New Drug Approval process. Until then, Stop Gas Station Heroin is calling for the immediate removal of these synthetic street drugs from store shelves. About Stop Gas Station Heroin Stop Gas Station Heroin is a national coalition that aims to educate consumers about harmful synthetic drugs and advocate for smart regulation that distinguishes between legitimate, natural botanicals and dangerous, synthetic drugs, combined with enforcement of current federal laws around unapproved drugs. To learn more, navigate to Media Contact Colby Wilson [email protected] ### SOURCE: Stop Gas Station Heroin Copyright 2025 EZ Newswire
